| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/17425255.2011.577740 |
| P698 | PubMed publication ID | 21510823 |
| P2093 | author name string | David E Amacher | |
| P2860 | cites work | Effects of AMPK activators on the sub-cellular distribution of fatty acid transporters CD36 and FABPpm. | Q45990586 |
| Insulin stimulation of the fatty acid synthase promoter is mediated by the phosphatidylinositol 3-kinase pathway. Involvement of protein kinase B/Akt | Q46255197 | ||
| Gene expression profiles of murine fatty liver induced by the administration of methotrexate | Q46479664 | ||
| Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis | Q46572857 | ||
| Gene expression profiling in livers of mice after acute inhibition of beta-oxidation. | Q46953374 | ||
| Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone | Q50195151 | ||
| Hepatic gene expression profiling and lipid homeostasis in mice exposed to steatogenic drug, tetracycline. | Q52009534 | ||
| 5-lipoxygenase activating protein signals adipose tissue inflammation and lipid dysfunction in experimental obesity. | Q54438381 | ||
| The subcellular localization of acetyl-CoA carboxylase 2 | Q22253198 | ||
| Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER | Q24305459 | ||
| Endoplasmic reticulum stress: cell life and death decisions. | Q24536108 | ||
| AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity | Q24595845 | ||
| Biochemical effects of SIRT1 activators | Q24633830 | ||
| Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis | Q27489896 | ||
| Membrane topology of human insig-1, a protein regulator of lipid synthesis | Q28189898 | ||
| Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1 | Q28237795 | ||
| Acetyl-coenzyme A carboxylase: crucial metabolic enzyme and attractive target for drug discovery | Q28257735 | ||
| Tetracycline-induced steatosis in primary canine hepatocyte cultures | Q28259765 | ||
| Investigation into the mechanism of tetracycline-induced steatosis: study in isolated hepatocytes | Q28263772 | ||
| Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles | Q40720835 | ||
| Regulation of hepatic de novo lipogenesis in humans | Q41138438 | ||
| Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines | Q41515973 | ||
| UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators. | Q42041480 | ||
| Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling | Q42440719 | ||
| Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis | Q42644245 | ||
| Zonation of fatty acid metabolism in rat liver | Q42804556 | ||
| Coupling endoplasmic reticulum stress to the cell death program. An Apaf-1-independent intrinsic pathway | Q42817119 | ||
| Calcium-antagonists inhibit secretion of very-low-density lipoprotein from cultured rat hepatocytes | Q42857006 | ||
| Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis. | Q42958285 | ||
| Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. | Q43192418 | ||
| Decreased microsomal triglyceride transfer protein activity contributes to initiation of alcoholic liver steatosis in rats | Q43878343 | ||
| Nile Red binding to HepG2 cells: an improved assay for in vitro studies of hepatosteatosis | Q43887936 | ||
| Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy | Q44254872 | ||
| Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. | Q44493753 | ||
| ChREBP: a glucose-activated transcription factor involved in the development of metabolic syndrome | Q28280671 | ||
| Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects | Q28281779 | ||
| Acute and chronic drug-induced hepatitis | Q28288881 | ||
| SREBP transcription factors: master regulators of lipid homeostasis | Q28297603 | ||
| ER chaperones in mammalian development and human diseases | Q28300625 | ||
| Regulation of hepatic lipogenesis by the transcription factor XBP1 | Q28507784 | ||
| The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR | Q28513664 | ||
| Modulation of the hepatic malonyl-CoA-carnitine palmitoyltransferase 1A partnership creates a metabolic switch allowing oxidation of de novo fatty acids | Q28573526 | ||
| Rapamycin inhibits postprandial-mediated X-box-binding protein-1 splicing in rat liver | Q28577788 | ||
| Hepatic de novo lipogenesis is present in liver-specific ACC1-deficient mice | Q28589371 | ||
| SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver | Q29547646 | ||
| Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease | Q29619334 | ||
| Activation of PPARalpha and PPARgamma reduces triacylglycerol synthesis in rat hepatoma cells by reduction of nuclear SREBP-1. | Q30319146 | ||
| The role of the carnitine system in human metabolism | Q33209774 | ||
| In vitro assay for drug-induced hepatosteatosis using rat primary hepatocytes, a fluorescent lipid analog and gene expression analysis | Q33410175 | ||
| Involvement of adiponectin-SIRT1-AMPK signaling in the protective action of rosiglitazone against alcoholic fatty liver in mice | Q33727352 | ||
| Cellular fatty acid uptake: a pathway under construction | Q33753883 | ||
| Regulation of hepatic gene expression by saturated fatty acids | Q33816670 | ||
| The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD). | Q33864337 | ||
| Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders | Q33899480 | ||
| CCAAT/enhancer-binding protein beta deletion reduces adiposity, hepatic steatosis, and diabetes in Lepr(db/db) mice | Q33943164 | ||
| Adiponectin--a key adipokine in the metabolic syndrome | Q33995313 | ||
| Insulin- and leptin-regulated fatty acid uptake plays a key causal role in hepatic steatosis in mice with intact leptin signaling but not in ob/ob or db/db mice | Q34212126 | ||
| Mitochondrial expression of the human equilibrative nucleoside transporter 1 (hENT1) results in enhanced mitochondrial toxicity of antiviral drugs. | Q34275557 | ||
| A new concept of cellular uptake and intracellular trafficking of long-chain fatty acids | Q34449774 | ||
| Targeting Forkhead box O1 from the concept to metabolic diseases: lessons from mouse models | Q34514818 | ||
| Intersection of the unfolded protein response and hepatic lipid metabolism | Q34985745 | ||
| Specific role for acyl CoA:Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids | Q34989773 | ||
| Hepatotoxicity and Mechanism of Action of Haloalkanes: Carbon Tetrachloride as a Toxicological Model | Q35112180 | ||
| Peroxisome proliferator activated receptor alpha (PPARalpha) and PPAR gamma coactivator (PGC-1alpha) induce carnitine palmitoyltransferase IA (CPT-1A) via independent gene elements | Q35177180 | ||
| AMPK as a metabolic switch in rat muscle, liver and adipose tissue after exercise. | Q35178619 | ||
| Minireview: malonyl CoA, AMP-activated protein kinase, and adiposity | Q35538672 | ||
| Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease | Q35631353 | ||
| Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents | Q36183590 | ||
| Perhexiline | Q36795930 | ||
| PXR and LXR in hepatic steatosis: a new dog and an old dog with new tricks | Q37029302 | ||
| New approaches to target microsomal triglyceride transfer protein | Q37114977 | ||
| Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review | Q37130104 | ||
| FoxO1 integrates insulin signaling to VLDL production | Q37148966 | ||
| AMPK: Lessons from transgenic and knockout animals | Q37153612 | ||
| Carbohydrate responsive element binding protein and lipid homeostasis. | Q37156323 | ||
| Evidence for AMPK-dependent regulation of exocytosis of lipoproteins in a model liver cell line | Q37235258 | ||
| Sensitivity of lipid metabolism and insulin signaling to genetic alterations in hepatic peroxisome proliferator-activated receptor-gamma coactivator-1alpha expression | Q37236343 | ||
| Dissecting the role of the 3-phosphoinositide-dependent protein kinase-1 (PDK1) signalling pathways. | Q37273269 | ||
| The constitutive androstane receptor is an anti-obesity nuclear receptor that improves insulin sensitivity | Q37377724 | ||
| Metabolic benefits from Sirt1 and Sirt1 activators | Q37498181 | ||
| Adiponectin: a key adipokine in alcoholic fatty liver | Q37505809 | ||
| Nutritional related liver disease: targeting the endoplasmic reticulum stress | Q37591100 | ||
| From sugar to fat: How the transcription factor XBP1 regulates hepatic lipogenesis | Q37596560 | ||
| PPAR control: it's SIRTainly as easy as PGC. | Q37601091 | ||
| Sirtuins regulate key aspects of lipid metabolism | Q37644807 | ||
| The Akt-SREBP nexus: cell signaling meets lipid metabolism. | Q37684518 | ||
| Insulin signaling meets mitochondria in metabolism | Q37715179 | ||
| The liver X receptor: control of cellular lipid homeostasis and beyond Implications for drug design | Q37723782 | ||
| Endoplasmic reticulum stress: a new actor in the development of hepatic steatosis. | Q37750327 | ||
| Endogenous ligand for an orphan receptor | Q37760605 | ||
| Hormonal and nutritional regulation of SCD1 gene expression. | Q37780318 | ||
| Strategies for the early detection of drug-induced hepatic steatosis in preclinical drug safety evaluation studies | Q37802944 | ||
| Histopathologic analysis of suspected amiodarone hepatotoxicity | Q38138053 | ||
| Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice. | Q38289104 | ||
| Gene expression in human NAFLD. | Q38292078 | ||
| Molecular characterization of the role of orphan receptor small heterodimer partner in development of fatty liver | Q38301398 | ||
| The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes | Q39451469 | ||
| Activation of the aryl hydrocarbon receptor induces hepatic steatosis via the upregulation of fatty acid transport | Q39657152 | ||
| Cytometric analysis for drug-induced steatosis in HepG2 cells. | Q39818123 | ||
| Involvement of mammalian sirtuin 1 in the action of ethanol in the liver | Q40018296 | ||
| Inhibiting proteasomal degradation of microsomal triglyceride transfer protein prevents CCl4-induced steatosis. | Q40150277 | ||
| Identification of the mitochondrial targeting signal of the human equilibrative nucleoside transporter 1 (hENT1): implications for interspecies differences in mitochondrial toxicity of fialuridine | Q40295834 | ||
| Microvesicular steatosis induced by a short chain fatty acid: effects on mitochondrial function and correlation with gene expression. | Q40473332 | ||
| Disruption of hepatic lipid homeostasis in mice after amiodarone treatment is associated with peroxisome proliferator-activated receptor-alpha target gene activation | Q40533066 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | steatosis | Q1365091 |
| P304 | page(s) | 949-965 | |
| P577 | publication date | 2011-04-21 | |
| P1433 | published in | Expert Opinion on Drug Metabolism & Toxicology | Q5421205 |
| P1476 | title | The mechanistic basis for the induction of hepatic steatosis by xenobiotics | |
| P478 | volume | 7 |
| Q42707141 | A simple transcriptomic signature able to predict drug-induced hepatic steatosis. |
| Q38539524 | Adverse Outcome Pathways and Drug-Induced Liver Injury Testing |
| Q33703437 | Adverse Outcome Pathways as Tools to Assess Drug-Induced Toxicity. |
| Q37732375 | Circulating microRNA 122 in the methionine and choline-deficient mouse model of non-alcoholic steatohepatitis |
| Q56541717 | Drug-induced steatohepatitis |
| Q34907809 | Identification of novel clinical factors associated with hepatic fat accumulation in extreme obesity. |
| Q53603517 | In vitro assessment of drug-induced liver steatosis based on human dermal stem cell-derived hepatic cells. |
| Q39023093 | Mechanisms of amiodarone and valproic acid induced liver steatosis in mouse in vivo act as a template for other hepatotoxicity models |
| Q36764809 | Mechanistically linked serum miRNAs distinguish between drug induced and fatty liver disease of different grades |
| Q28539289 | Model steatogenic compounds (amiodarone, valproic acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices |
Search more.